Document is current

Article History

Received: 12 December 2022

Accepted: 21 February 2023

First Online: 1 March 2023

Declarations

:

: This study was approved by the Institutional Review Board (Saitama Medical University) and conducted according to the Declaration of Helsinki. All patients provided written informed consent before participation and could withdraw from the study at any time. This trial was registered in the Japan Registry of Clinical Trials (registration no. jRCTs031180036; dated: 01/11/2018).

: Not applicable.

: KK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Boehringer Ingelheim, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan, Nihon Medi-Physics Co.,Ltd. and AstraZeneca. OY have received a speaker honorarium from Eli Lilly, Taiho Pharmaceutical, Pfizer, Chugai Pharmaceutical, and AstraZeneca. AM have received a speaker honorarium from Ono Pharmaceutical Company, Taiho Pharmaceutical, Pfizer, Daiichi Sankyo Company, Merck Biopharma Company, Novartis Pharma, Thermo Fisher Scientific, Chugai Pharmaceutical, and AstraZeneca. HK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Bristol-Myers Company, Boehringer Ingelheim, MSD, Daiichi Sankyo Company, Chugai Pharmaceutical, Taiho Pharmaceutical, Merck Biopharma Company, Eli Lilly Japan, and AstraZeneca. SW has received grants and a speaker honorarium from AstraZeneca, Eli Lilly and Boehringer Ingelheim, a speaker honorarium from Chugai Pharma, Ono Pharmaceutical, Bristol-Myers, MSD, Taiho Pharmaceutical, Pfizer, Novartis and Daiichi Sankyo. KI received research grants and a speaker honorarium from AstraZeneca, Chugai Pharma, Bristol-Myers, Boehringer Ingelheim, Ono Pharmaceutical, Taiho Pharmaceutical, Novartis International AG, Daiichi Sankyo Company. NS has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Bristol-Myers Company, MSD, AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, Pfizer Japan, Eli Lilly Japan, Taiho Pharmaceutical, Daiichi Sankyo Company, and Merck Biopharma Company. IK has received research grants from FUJIFILM Toyama Chemical Co., Ltd. and Nihon Medi-Physics Co.,Ltd. All other authors declare no potential conflict of interest.